Zolpidem

Evidence Level: L5

Predicted Indications: 2

Zolpidem

Pharmacist Assessment Report

Zolpidem: Benign paroxysmal torticollis of infancy

One-Sentence Summary

Zolpidem is a sedative-hypnotic originally used to treat insomnia. The TxGNN model predicts it may be effective for benign paroxysmal torticollis of infancy, with no registered clinical trials and 20 publications (including network meta-analyses and clinical guidelines) currently supporting this direction. Because this predicted indication is essentially the same as the drug’s established use, it is better seen as confirmation of an existing indication than as true repurposing.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Benign paroxysmal torticollis of infancy
TxGNN Prediction Score	0.9926
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 12 of 12)
Number of DINs	12 (marketed: 12)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not available in the data compiled for this report. Based on the mechanistic assessment, zolpidem is a positive allosteric modulator of the GABA-A receptor with preferential affinity for the alpha-1 subunit. This produces sedative-hypnotic effects.

The publications reviewed describe zolpidem as a “Z-drug” (with zopiclone, eszopiclone and zaleplon) that is widely used for insomnia. They also note that it carries risks of cognitive impairment, falls, dependence and next-day impairment, particularly in older adults.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35843245	2022	Network meta-analysis	Lancet	Compared pharmacological treatments for acute and long-term management of insomnia disorder in adults
27998379	2017	Clinical practice guideline (AASM)	J Clin Sleep Med	Recommendations for individual drugs used to treat chronic insomnia in adults
31880796	2019	RCT (Phase 3)	JAMA Netw Open	Lemborexant vs placebo and zolpidem extended release (active comparator) in older adults with insomnia
34121443	2021	Network meta-analysis	J Manag Care Spec Pharm	Compared efficacy and safety of lemborexant with other insomnia treatments
37549414	2023	Review	J Fam Pract	Insomnia is underrecognized and undertreated in primary care; treating it improves outcomes
29487083	2018	Review	Pharmacol Rev	Z-drugs are effective but have side effects including cognitive impairment, tolerance, falls, abuse and dependence
27751669	2016	Review	Clin Ther	Safety and efficacy of sleep medicines in older adults
30058034	2018	Review	Drugs Aging	Pharmacological management recommendations for insomnia in elderly patients
22424586	2012	Review	Expert Opin Pharmacother	Zolpidem is a benzodiazepine receptor agonist and the most widely prescribed hypnotic in the US
16696581	2006	Review	CNS Drugs	Zolpidem extended-release, a dual-layer formulation for sleep onset and maintenance

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02391678	SUBLINOX	Not specified	Not specified
02370433	SUBLINOX	Not specified	Not specified
02434946	APO-ZOLPIDEM ODT	Not specified	Not specified
02436159	APO-ZOLPIDEM ODT	Not specified	Not specified
02472821	MINT-ZOLPIDEM ODT	Not specified	Not specified

Twelve valid single-ingredient licences are held in total. The remaining seven are other zolpidem ODT products from JAMP, PRO and PMS.

Safety Considerations

Contraindication signals (from the knowledge graph, not label text): anxiety disorder, neurotic disorder, dysthymic disorder, liver disease, gallbladder disease, obstructive sleep apnea syndrome, sleep apnea syndrome, congenital central hypoventilation syndrome, amnestic disorder, retrograde amnesia, substance-related disorder, substance abuse/dependence, and attention deficit hyperactivity disorder.
Key warnings (from the mechanistic assessment): complex sleep behaviors (boxed warning), next-day impairment, and increased risk in older adults.
Drug interactions: 100 interactions were identified. Major interactions include morphine and liposomal morphine. Moderate interactions include opium, bupropion, aprepitant, dexamethasone, cimetidine, clarithromycin, dronabinol, nabilone, metoclopramide, miconazole and clotrimazole. The risk is greatest with other CNS depressants.

Please refer to the package insert for the full label warnings and contraindications.

Other Predicted Indications (Low Evidence)

Predicted Indication	TxGNN Score	Evidence Level	Decision	Comment
Benign paroxysmal torticollis of infancy	0.9926	L5	Hold	No plausible mechanistic link. The condition is self-limiting and sedative-hypnotics raise safety concerns in infants.
Agoraphobia	0.9925	L5	Hold	Only a weak rationale. Zolpidem has minimal anxiolytic activity, first-line treatments are established, and Z-drugs carry dependence and misuse potential.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The predicted indication essentially matches zolpidem’s established use in insomnia, and it is supported by network meta-analyses and clinical guidelines. It is also marketed in Canada under 12 licences. No clinical trials are registered for this specific predicted indication, and the safety burden is significant.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
Detailed mechanism of action data from DrugBank
Approved indication text and dosage forms for the Canadian licences
A risk-management plan for complex sleep behaviors, next-day impairment, use in older adults, and co-prescription with CNS depressants and opioids
If true repurposing is intended, a clearly distinct target indication, since the two other predictions (benign paroxysmal torticollis of infancy and agoraphobia) lack supporting evidence and should remain on hold
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.